April 29, 2021: -Pfizer’s experimental oral drug to treat Covid-19 at the first sign of illness could be available by this year-end, CEO Albert Bourla told CNBC on Tuesday.
The company that developed the first authorized Covid-19 vaccine in the U.S. with German drugmaker BioNTech started in March an early-stage clinical trial that tested a new antiviral therapy for treating the disease.
The drug is a class of protease inhibitors and works by inhibiting an enzyme that the virus should replicate in human cells.
Protease inhibitors are also used to treat other viral pathogens like HIV and hepatitis C.
If clinical trials are successful and the Food and Drug Administration approves it, the drug could be distributed all around the U.S. by the year-end, Bourla told CNBC.
Health experts say the drug, taken by mouth, could be a game-changer because people who are infected with the virus recently could use it outside of hospitals.
Researchers are hoping that this can lower the hospital trips, and the medication will keep the disease from increasing.
In addition to the drug, Pfizer is still testing its vaccine in 6-month to 11-year-old children. Vaccinating children is crucial to ending the coronavirus pandemic, according to public health officials and infectious disease experts.
Earlier this month, the company asked the FDA to expand its vaccine authorization to adolescents ages 12 to 15 after the dose was 100% effective in a study. Bourla is “very optimistic” that the FDA will approve the use of the shot in adolescents, he told CNBC on Tuesday.
We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.
September 26, 2023: On Monday, Japanese automaker Nissan revealed its dedication to transitioning to completely electric …
In an industry as competitive and fast-paced as Consumer Packaged Goods (CPG), standing out from the crowd requires innovation and adaptability. The cracks in the CPG supply chain were exposed long before the global pandemic struck, but the events of the past year only exacerbated the weaknesses.
Supply chain leaders, including VPs, often find themselves making bets with unknown financial consequences. Having started with largely infeasible plans generated by deterministic “one-number” planning systems, compounded by unexpected supply or demand disruptions, they are forced into last-minute adjustments to meet operational and financial goals.
Unsurprisingly, today’s supply chain faces numerous issues, including sustainability, technology, global economic and political instability, talent management, and supply chain resilience. Advanced forecasting algorithms and predictive analytics are used in supply chain management to help organizations of all sizes make better decisions by providing insights into what’s going on in their business at any given moment and predicting future trends.
Ensuring the right products are in the right place and at the right time is critical for companies also dealing with supply chain constraints and a high degree of variability. Uncertainty has become the name of the game and the only way to effectively optimize inventory through continuous, data-driven assessments, planning, and decision-making.
Food Huggers, a consumer brand that designs products to reduce waste at home, may be in an enviable position now but before they found Extensiv Order Manager, managing booming orders and staying on top of inventory was a huge operational challenge. The business has inventory spread across multiple geographically distributed warehouses, with orders received via multiple sales channels, including Shopify storefronts and Amazon.